文献速递小儿眼科与斜弱视

原发性遮盖治疗在非对称性双侧弱视中的效果

Effect of Primary Occlusion Therapy in Asymmetric, Bilateral Amblyopia.
PubMed 文献 · Am J Ophthalmol · 2019-11-09

本研究回顾性比较非对称性双侧弱视患者原发性与继发性遮盖治疗的视力结局。98例患儿分组后,两组双眼视力、眼间差异及立体视改善相似,继发性遮盖组在12-18个月时更易达到双眼20/30且眼间差异≤1行,但末次随访时无差异。原发性遮盖相比单纯屈光矫正无额外获益。

要点

  • 非对称性双侧弱视患者中,原发性遮盖相比单纯屈光矫正无额外视力获益。
  • 继发性遮盖在12-18个月时更易达到双眼20/30且眼间差异≤1行,但末次随访时两组无差异。
  • 无论遮盖时机,弱眼视力平均提高4行,强眼提高2行,眼间差异改善2行。

核心结论

  • 在非对称性双侧弱视患者中,无论是否进行遮盖治疗,弱眼视力提高约4行,强眼提高约2行,眼间差异改善约2行。
  • 原发性遮盖相比单纯屈光矫正未提供额外获益。

研究设计与样本

  • 回顾性介入比较病例系列,纳入2010至2014年波士顿儿童医院诊断的弱视患者。
  • 共审查2200例患者,167例(7.6%)为非对称性双侧弱视,98例符合纳入和排除标准。
  • 患者分为原发性遮盖组(n=50)和继发性遮盖组(n=48),比较12-18个月及末次随访的视力改善。

主要发现

  • 两组在人口学特征、基线视力及眼间差异上无差异(P ≥ .22),但原发性遮盖组斜视性弱视比例更高(P = .007)。
  • 两组双眼视力、眼间差异及立体视改善相似,即使按弱视亚型分层后仍相似(P ≥ .48)。
  • 继发性遮盖组在12-18个月时更可能达到双眼20/30且眼间差异≤1行(P ≤ .4),但末次随访时两组趋于一致。

关键数值与推荐

  • 纳入标准:双眼视力≥0.3 logMAR(客观视标测量),眼间差异≥0.18 logMAR,年龄2-12岁。
  • 排除标准:失访、手术治疗、剥夺性弱视。
  • 原发性遮盖定义为双眼视力≥0.3 logMAR时开始遮盖;继发性遮盖定义为强眼视力改善至≤0.18 logMAR后为纠正残余眼间差异而开始遮盖。

临床怎么用

  • 对于非对称性双侧弱视,可先进行屈光矫正并观察,原发性遮盖未显示额外获益。
  • 继发性遮盖可能在12-18个月时更易达到双眼20/30且眼间差异≤1行,但长期结局与原发性遮盖相似。

局限性

  • 回顾性研究设计。
  • 原发性遮盖组斜视性弱视比例更高,可能存在混杂。
  • 样本量有限,仅纳入98例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Many bilateral amblyopia patients have asymmetric visual acuity (VA). There is no standard treatment for these patients, and outcomes have not been well described. Our goal is to compare VA outcomes in this group based on timing of occlusion therapy. DESIGN: Retrospective interventional comparative case series. METHODS: Setting: Institutional practice. PatientPopulation: Patients diagnosed with amblyopia at Boston Children's Hospital between 2010 and 2014. InclusionCriteria: VA ≥ 0.3 logMAR bilaterally by objective optotype-based measures, interocular difference (IOD) ≥ 0.18 logMAR, age 2-12 years. ExclusionCriteria: Loss to follow-up, managed surgically, deprivation amblyopia. Patients had either primary or secondary occlusion (primary = initiated when VA ≥ 0.3 logMAR bilaterally; secondary = initiated to correct residual IOD once VA improved to ≤0.18 logMAR in the stronger eye). ObservationProcedure: Patient demographics, VA, IOD, and stereopsis were compared between groups. OutcomeMeasures: VA improvement at 12-18 months and at last visits. RESULTS: Of 2,200 patients reviewed, 167 (7.6%) had asymmetric, bilateral amblyopia; 98 met inclusion and exclusion criteria. Patients were equally divided between primary (n = 50) and secondary (n = 48) occlusion groups. There were no differences in demographics, baseline VA, or IOD between groups (P ≥ .22), although the primary occlusion group had a higher proportion of strabismic amblyopia (P = .007). VA in both eyes, IOD, and stereopsis improved similarly between groups, even after stratifying by amblyopia subtype (P ≥ .48). The secondary occlusion group was more likely to achieve 20/30 bilaterally and IOD ≤ 1 line at 12-18 months (P ≤ .4), although this equalized by the last visit. CONCLUSION: In patients with asymmetric, bilateral amblyopia, VA improved by 4 lines in the weaker eye and 2 lines in the stronger eye, while IOD improved by 2 lines, irrespective of occlusion status. Primary occlusion thus provided no further benefit over spectacle correction alone.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shoshany TN, Michalak S, Staffa SJ, et al. Effect of Primary Occlusion Therapy in Asymmetric, Bilateral Amblyopia. Am J Ophthalmol. 2019. PMID: 31712066. doi:10.1016/j.ajo.2019.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。